Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Broomall, Pennsylvania 19008


Purpose:

The objective of this study is to determine the relative gentleness of two tapes recognized for gentleness. A three-prong multidimensional evaluation consisting of laboratory assessments, expert skin grader and subject discomfort assessment will be used.


Study summary:

The objective of this study is to determine the relative gentleness of a new investigational tape compared to 3M Micropore tape, a gold standard tape recognized for its gentleness and used as a mainstay in cosmetic surgery and neonatal care. A three-prong multidimensional evaluation consisting of laboratory assessments, expert skin grader and subject discomfort assessment will be used.


Criteria:

Inclusion Criteria: 1. Who are healthy and who have intact skin at the test site with a baseline score of 0 for erythema 2. Who are between the ages of 6 months - 4 years of age 3. Who has a Fitzpatrick Skin Type of I, II or III 4. Subject who's parent agrees to not use any products (i.e. topical medications, creams, powders or ointments) on the test sites for 24 hours prior to the study start date 5. Whose parent is willing to sign the Informed Consent Form. Exclusion Criteria: 1. Who are known to be developmentally delayed 2. Who have sunburn, skin infection or scars, moles, or other blemishes on the back that would obscure grading of the test sites 3. Who have had any exposure to other topical medications, creams, powders, or ointments on the test sites 24 hours prior to the start of the study. 4. Who have had a strep infection within the past 2 weeks 5. Who have a history of diabetes, psoriasis, any active dermatitis, or recent history of dermatitis or skin reactions 6. Who have allergies to isocyanates, or acrylate adhesive products 7. Who currently take any antihistamines or anti-inflammatory medication or who have taken any of these medications within 48 hours prior to the start of the study or does not agree to refrain from taking these medications for the 48 hours prior to the start of the study and for the duration of the study (Tylenol is an acceptable pain reliever).


NCT ID:

NCT01354106


Primary Contact:

Principal Investigator
Gary L Grove, PhD
cyberDERM


Backup Contact:

N/A


Location Contact:

Broomall, Pennsylvania 19008
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.